ZLAB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZLAB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Zai Lab's Total Assets for the quarter that ended in Dec. 2024 was $1,185.8 Mil.
During the past 12 months, Zai Lab's average Total Assets Growth Rate was 76.70% per year. During the past 3 years, the average Total Assets Growth Rate was 26.40% per year. During the past 5 years, the average Total Assets Growth Rate was 34.70% per year.
During the past 10 years, Zai Lab's highest 3-Year average Total Assets Growth Rate was 267.60%. The lowest was 26.40%. And the median was 73.20%.
Total Assets is connected with ROA %. Zai Lab's annualized ROA % for the quarter that ended in Dec. 2024 was -30.10%. Total Assets is also linked to Revenue through Asset Turnover. Zai Lab's Asset Turnover for the quarter that ended in Dec. 2024 was 0.10.
The historical data trend for Zai Lab's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Total Assets | Get a 7-Day Free Trial |
![]() |
![]() |
1,297.64 | 1,609.96 | 1,220.14 | 1,036.30 | 1,185.75 |
Zai Lab Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Total Assets | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
1,036.30 | 988.44 | 987.37 | 985.35 | 1,185.75 |
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Zai Lab's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
Total Assets | = | Total Equity (A: Dec. 2024 ) | + | Total Liabilities (A: Dec. 2024 ) |
= | 840.898 | + | 344.855 | |
= | 1,185.8 |
Zai Lab's Total Assets for the quarter that ended in Dec. 2024 is calculated as
Total Assets | = | Total Equity (Q: Dec. 2024 ) | + | Total Liabilities (Q: Dec. 2024 ) |
= | 840.898 | + | 344.855 | |
= | 1,185.8 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab (NAS:ZLAB) Total Assets Explanation
Total Assets is connected with ROA %.
Zai Lab's annualized ROA % for the quarter that ended in Dec. 2024 is
ROA % | = | Net Income (Q: Dec. 2024 ) | / | ( (Total Assets (Q: Sep. 2024 ) | + | Total Assets (Q: Dec. 2024 )) | / count ) |
= | -326.736 | / | ( (985.346 | + | 1185.753) | / 2 ) | |
= | -326.736 | / | 1085.5495 | ||||
= | -30.10 % |
Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Zai Lab's Asset Turnover for the quarter that ended in Dec. 2024 is
Asset Turnover | ||||||
= | Revenue (Q: Dec. 2024 ) | / | ( (Total Assets (Q: Sep. 2024 ) | + | Total Assets (Q: Dec. 2024 )) | / count ) |
= | 109.07 | / | ( (985.346 | + | 1185.753) | / 2 ) |
= | 109.07 | / | 1085.5495 | |||
= | 0.10 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Thank you for viewing the detailed overview of Zai Lab's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Rafael Amado | officer: See Remarks | 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Ying Du | director, officer: Chairwoman & CEO | C/O ZAID LAB LIMITED, 4560 JINKE ROAD, BLDG. 1, 4F, PUDONG, SHANGHAI F4 201210 |
Richard Gaynor | director | C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139 |
Yajing Chen | officer: Chief Financial Officer | 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE MA 02142 |
Edmondson Frazor Titus Iii | officer: Chief Legal Officer | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
Joshua L Smiley | officer: Chief Operating Officer | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
William Lis | director | PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Kai-xian Chen | director | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
Harald Reinhart | officer: Chief Medical Officer | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
Michel Vounatsos | director | BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Peter Wirth | director | 37 HANCOCK STREET, BOSTON MA 02114 |
John D Diekman | director | C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Tao Fu | director, officer: President & COO | 3175 HANOVER STREET, PALO ALTO CA 94304 |
Scott W Morrison | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Cho William Ki Chul | officer: Chief Financial Officer | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
From GuruFocus
By GuruFocus News • 01-17-2025
By GuruFocus News • 12-12-2024
By GuruFocus News • 02-28-2025
By GuruFocus News • 03-03-2025
By Business Wire • 11-21-2024
By Business Wire • 02-27-2025
By GuruFocus News • 01-10-2025
By GuruFocus News • 02-27-2025
By Business Wire • 12-12-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.